Two Aryl Rings Or Aryl Ring Systems Bonded Directly To The Same Acyclic Carbon Patents (Class 514/648)
-
Patent number: 12071391Abstract: The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.Type: GrantFiled: March 30, 2023Date of Patent: August 27, 2024Assignee: ATOSSA THERAPEUTICS, INC.Inventors: Steven C. Quay, Yao-Lin Sun, LungHu Wang, ChangJung Wu, ChuanDer Huang
-
Patent number: 11850308Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.Type: GrantFiled: December 22, 2021Date of Patent: December 26, 2023Assignee: Bonafide Health, LLCInventor: James R. Komorowski
-
Patent number: 11801224Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.Type: GrantFiled: March 4, 2022Date of Patent: October 31, 2023Assignee: JDS THERAPEUTICS, LLCInventor: James R. Komorowski
-
Patent number: 11680036Abstract: The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.Type: GrantFiled: December 29, 2022Date of Patent: June 20, 2023Assignee: ATOSSA THERAPEUTICS, INC.Inventors: Steven C. Quay, Yao-Lin Sun, LungHu Wang, ChangJung Wu, ChuanDer Huang
-
Patent number: 11623968Abstract: A method for making xanthan gum copolymer nanomicelles comprising: 1) degrading xanthan gum in aqueous solution to obtain degraded xanthan gum; 2) preparing xanthan gum bromide from the degraded xanthan gum; 3) preparing xanthan gum copolymer from the xanthan gum bromide and 4) making the gum copolymer nanomicelles from the xanthan gum copolymer. The xanthan gum copolymer nanomicelles have good morphological regularity, good biocompatibility and stable performance as an anticancer drug carriers.Type: GrantFiled: November 26, 2019Date of Patent: April 11, 2023Assignee: JIANGNAN UNIVERSITYInventors: Liping Zhang, Caihua Ni, Ren Liu, Gang Wang
-
Patent number: 11572334Abstract: The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.Type: GrantFiled: January 20, 2022Date of Patent: February 7, 2023Assignee: ATOSSA THERAPEUTICS, INC.Inventors: Steven C. Quay, Yao-Lin Sun, LungHu Wang, ChangJung Wu, ChuanDer Huang
-
Patent number: 11426366Abstract: This invention provides methods utilizing ketamine for the treatment of motor disorders and/or side effects associated with certain medications used in the treatment of motor disorders. For example, in some embodiments, methods are provided for treating side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of ketamine or a pharmaceutically acceptable salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with motor disorder (e.g., Parkinson's disease) treatments, and effective doses of ketamine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2016Date of Patent: August 30, 2022Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSSITY OF ARIZONAInventors: Scott Sherman, Torsten Falk, Miguel Estevez
-
Patent number: 11191738Abstract: The use of tamoxifen or a pharmaceutically acceptable salt as non estrogen-dependent acting drug for the treatment of cystic fibrosis in patients of both sexes is disclosed. Tamoxifen is preferably administered by inhalation route.Type: GrantFiled: April 3, 2017Date of Patent: December 7, 2021Assignee: GB PHARMA S.R.L.Inventor: Giorgio Balduzzi
-
Patent number: 11138441Abstract: Embodiments herein treat the action segmentation as a domain adaption (DA) problem and reduce the domain discrepancy by performing unsupervised DA with auxiliary unlabeled videos. In one or more embodiments, to reduce domain discrepancy for both the spatial and temporal directions, embodiments of a Mixed Temporal Domain Adaptation (MTDA) approach are presented to jointly align frame-level and video-level embedded feature spaces across domains, and, in one or more embodiments, further integrate with a domain attention mechanism to focus on aligning the frame-level features with higher domain discrepancy, leading to more effective domain adaptation. Comprehensive experiment results validate that embodiments outperform previous state-of-the-art methods. Embodiments can adapt models effectively by using auxiliary unlabeled videos, leading to further applications of large-scale problems, such as video surveillance and human activity analysis.Type: GrantFiled: December 6, 2019Date of Patent: October 5, 2021Assignee: Baidu USA LLCInventors: Baopu Li, Min-Hung Chen, Yingze Bao
-
Patent number: 10786457Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: GrantFiled: April 10, 2018Date of Patent: September 29, 2020Assignee: THERAVIDA, INC.Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
-
Patent number: 10034832Abstract: Technologies are described for formulations and methods to produce sublingual antidepressant lozenges. The lozenges may comprise troche base and ketamine. The lozenges may comprise 0.35 weight percent to 0.65 weight percent ketamine. The methods may comprise placing troche base into a chamber. The methods may comprise applying heat to the chamber. The heat may be sufficient to melt the troche base in the chamber. The methods may comprise adding a first ingredient into the chamber. The first ingredient may include ketamine. The methods may comprise mixing the first ingredient into the melted troche base in the chamber to form a melted mixture. The methods may comprise pouring the melted mixture into a mold. The methods may comprise cooling the melted mixture in the mold to form the lozenge.Type: GrantFiled: February 13, 2017Date of Patent: July 31, 2018Assignee: Synergistic Therapeutics, LLCInventors: Anthony H. Salce, Jr., William F. Greenwood, Shivsankar Misir
-
Patent number: 9993583Abstract: Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.Type: GrantFiled: March 3, 2015Date of Patent: June 12, 2018Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC.Inventor: Ni Ding
-
Patent number: 9828330Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.Type: GrantFiled: March 14, 2014Date of Patent: November 28, 2017Assignee: PharmatrophiX, Inc.Inventor: Frank M. Longo
-
Patent number: 9682049Abstract: Non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, such as for example about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or about 3:1 by weight of D-methadone to L-methadone, have been found to exhibit surprising and unexpected beneficial results in the treatment of neuropathic pain. Additionally, non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or for example about 3:1 by weight of D-methadone to L-methadone, in combination with other non-methadone opioids have been found to exhibit surprising and unexpected beneficial results in the treatment of mixed pain.Type: GrantFiled: September 10, 2015Date of Patent: June 20, 2017Inventor: Y. Eugene Mironer
-
Patent number: 9422225Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.Type: GrantFiled: September 19, 2008Date of Patent: August 23, 2016Assignee: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 9315450Abstract: The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof.Type: GrantFiled: June 14, 2013Date of Patent: April 19, 2016Assignee: ratiopharm GmbHInventors: Simone Eichner, Wolfgang Albrecht
-
Patent number: 9308171Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: January 30, 2015Date of Patent: April 12, 2016Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 9308170Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: May 9, 2013Date of Patent: April 12, 2016Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 9212127Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R1 is C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; Z is NH, NCH3, O, S, or CH2; Y is NH, O, or CH2 with the proviso that Y and Z are not the same; R2 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R3 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy.Type: GrantFiled: August 22, 2005Date of Patent: December 15, 2015Assignee: University of Virginia Patent FoundationInventors: Lloyd S. Gray, Timothy L. MacDonald, Doris M. Haverstick, Jaclyn R. Patterson, William F. McCalmont
-
Patent number: 9101668Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.Type: GrantFiled: August 1, 2013Date of Patent: August 11, 2015Assignees: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
-
Patent number: 9072700Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: GrantFiled: December 23, 2013Date of Patent: July 7, 2015Assignee: Sunovion Pharmaceuticals Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20150126611Abstract: 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine (fendiline): as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activity. This invention concerns the prototypical profile of selective sigma-1 ligand and the putative therapeutical properties of the compound 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine (DPPA) and its pharmaceutically acceptable salts, with cytoprotective activity, more specifically for neurons against the neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease) via their anti-apoptotic properties induced by their selective sigma-1 agonism. Concerning the cancer cells, DPPA exhibited pro-apoptotic properties associated with neuroprotective activity originating a prototypical anticancer profile consisting in synergistical association with the clinically used anticancer drugs with its analgesic and neuroprotective activities antagonizing the neuropathic pain induced by the later.Type: ApplicationFiled: January 8, 2013Publication date: May 7, 2015Inventor: VAMVAKIDES Alexandre
-
Patent number: 9023841Abstract: This disclosure provides methods for treating asthma or an associated disorder in a patient in need thereof, by administering to the patient an effective amount of an autophagy inducing agent, thereby treating the asthma or the associated disorder. Disorders that can be treated include, allergic asthma, chronic obstructive pulmonary disease, lung inflammation, respiratory tolerance and a lung infection or disorder.Type: GrantFiled: August 2, 2012Date of Patent: May 5, 2015Assignee: University of Southern CaliforniaInventor: Omid Akbari
-
Publication number: 20150111970Abstract: This application provides a method to identify genetic markers associated with increased sensitivity or resistance to hormonal therapies using an outlier analysis. More specifically, this application discloses that amplifications on chromosomes 8 and 17 are associated with increased proliferation and poor outcome in ER-positive breast cancer, and amplicons 17q21.33-q25.1, 8p11.2 and 8q24.3 may be responsible for higher proliferation and poor outcome in the setting of antiestrogen, in particular Tamoxifen, treatment clinically observed in a subset of ER-positive, HER2-negative breast cancers. The invention also provides use of the identified genetic markers in the development of targeted treatments for antiestrogen-resistant ER-positive breast cancers as well as in improving current methods of drug response prediction.Type: ApplicationFiled: October 22, 2014Publication date: April 23, 2015Inventors: Erhan Bilal, Gyan Bhanot, Shrider Ganesan
-
Patent number: 9005637Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.Type: GrantFiled: April 5, 2013Date of Patent: April 14, 2015Assignee: JDS Therapeutics, LLCInventor: James R Komorowski
-
Publication number: 20150093365Abstract: Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.Type: ApplicationFiled: March 14, 2013Publication date: April 2, 2015Inventors: Xin Lu, Sarit S. Agasti, Ronald A. DePinho, Ralph Weissleder
-
Publication number: 20150086565Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20150080384Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Applicant: ACURA PHARMACEUTICALS, INC.Inventors: Ronald L. LEECH, Rachelle L. HALL YUNG, Albert W. BRZECZKO
-
Patent number: 8969326Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: GrantFiled: January 18, 2012Date of Patent: March 3, 2015Assignee: University of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Publication number: 20150051199Abstract: The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections.Type: ApplicationFiled: October 31, 2012Publication date: February 19, 2015Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Andrew James Woodhead, Christopher Charles Frederick Hamlett, Gilbert Ebai Besong, Gianni Chessari, Maria Grazia Carr, Alessia Millemaggi, David Norton, Susanne Maria Saalau-Bethell, Hendrika Maria Gerarda Willems, Neil Thomas Thompson, Steven Douglas Hiscock
-
Publication number: 20150038468Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Publication number: 20150031656Abstract: The present invention relates to a combination therapy for elevating testosterone levels in male mammals in which an antiestrogen or pharmaceutically acceptable salt thereof is co-administered to the mammal with an additional therapeutic agent selected from an androgen and an aromatase inhibitor. The invention is also directed to a combination therapy for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.Type: ApplicationFiled: February 28, 2013Publication date: January 29, 2015Inventors: Joseph S. Podolski, Ronald D. Wiehle
-
Publication number: 20150030666Abstract: The present invention provides an adhesive skin patch containing a support and an adhesive layer containing a drug which is formed on the support, wherein the adhesive layer comprises a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight per 100 parts by weight of the thermoplastic elastomer, a therapeutic drug having an anticholinergic activity or a salt thereof for overactive bladder as a drug, (A) a non-volatile hydrocarbon oil as a liquid component, and one or more kinds selected from the group consisting of (B) an amide solvent, (C) an alcohol solvent and (D) a liquid organic acid as a liquid component, or a fatty acid salt, and optionally comprises a tackifier at a content of not more than 10 wt % of the adhesive layer.Type: ApplicationFiled: November 28, 2012Publication date: January 29, 2015Inventors: Hiroyuki Ogino, Masaoki Goto, Atsuyo Hamada, Mitsuji Akazawa
-
Publication number: 20150031680Abstract: The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect.Type: ApplicationFiled: February 14, 2013Publication date: January 29, 2015Applicant: REPROS THERAPEUTICS INC.Inventors: Joseph S. Podolski, Ronald D. Wiehle
-
Publication number: 20150024035Abstract: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of methadone and a method of synthesising the same. The methadone entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder.Type: ApplicationFiled: July 21, 2014Publication date: January 22, 2015Applicant: KIMIA ZIST PARSIAN COInventor: Mehrdad Hamidi
-
Publication number: 20150017226Abstract: The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form of a free base in the adhesive base.Type: ApplicationFiled: December 25, 2012Publication date: January 15, 2015Inventors: Taiki Shibata, Kensuke Murata, Kenichi Hattori, Shinji Tanaka
-
Publication number: 20150018341Abstract: The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.Type: ApplicationFiled: December 28, 2012Publication date: January 15, 2015Applicant: CENTAURUS BIOPHARMA CO., LTD.Inventors: Dengming Xiao, Li Zhu, Yuandong Hu, Rong Yu, Wei Hu, Na Zhao, Yong Peng, Hong Luo, Yongxin Han
-
Publication number: 20150004216Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.Type: ApplicationFiled: September 19, 2014Publication date: January 1, 2015Inventor: Robert Steven Davidson
-
Publication number: 20140363503Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.Type: ApplicationFiled: June 27, 2014Publication date: December 11, 2014Inventors: EmadEldin M. Hassan, Warren Walter Kindt, Roger E. Gordon
-
Publication number: 20140363395Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.Type: ApplicationFiled: July 24, 2014Publication date: December 11, 2014Inventors: Theodore J. Nitz, Janet A. Gaboury, Christopher J. Burns, Sylvie Laquerre, Daniel C. Pevear, Thomas A. Lessen, David J. Rys
-
Patent number: 8906419Abstract: The present invention is directed to a process of preparing beads coated with a water soluble drug for incorporation into a pharmaceutical composition comprising: (a) preparing a supersaturated drug solution containing a desired amount of drug, which is completely saturated at a first temperature but which is supersaturated at a second temperature which is below the first temperature; and (b) coating inert beads with the drug solution, said drug solution being maintained at or below the first temperature but above the second temperature, and said beads maintained at a second temperature, wherein the second temperature is less than the first temperature and wherein the solution containing the drug is supersaturated at the second temperature, as well as to the pharmaceutical compositions containing same.Type: GrantFiled: January 24, 2011Date of Patent: December 9, 2014Assignee: Nostrum Pharmaceuticals, Inc.Inventor: Nirmal Mulye
-
Patent number: 8901175Abstract: The use of opioids or opioid mimetics is suggested for the manufacture of a medicament for the treatment of resistant cancer patients.Type: GrantFiled: January 29, 2009Date of Patent: December 2, 2014Assignee: Universität UlmInventors: Erich Miltner, Claudia Friesen, Andreas Alt
-
Patent number: 8901113Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.Type: GrantFiled: September 29, 2010Date of Patent: December 2, 2014Assignee: Acura Pharmaceuticals, Inc.Inventors: Ronald L. Leech, Rachelle L. Hall Yung, Albert W. Brzeczko
-
Publication number: 20140350117Abstract: The present disclosure describes a topical scar treatment composition that may include tamoxifen citrate in a concentration of about 0.01% by weight to about 1% by weight, with about 0.1% by weight being preferred, and an anhydrous silicone base for enhancing skin permeation and scar removing effects, in a concentration of about 10% by weight to about 100% by weight, with about 100% being preferred being preferred. The small concentration of tamoxifen citrate may prevent dangerous side effects and may be successful in treating abnormal scars such as keloids and hypertrophic scars.Type: ApplicationFiled: May 22, 2013Publication date: November 27, 2014Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICAInventor: Fabiana Campanati Banov
-
Patent number: 8895047Abstract: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.Type: GrantFiled: May 21, 2008Date of Patent: November 25, 2014Assignee: Arrow International, Inc.Inventors: Nisha Gupta, Joel Rosenblatt, Daniel J. Spangler
-
Publication number: 20140341988Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: APR APPLIED PHARMA RESEARCH SAInventors: Alberto REINER, Giorgio REINER
-
Patent number: 8871275Abstract: The present invention deals with extended release pharmaceutical compositions comprising tolterodine, wherein the composition comprises: a) a drug layer comprising tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition.Type: GrantFiled: August 6, 2008Date of Patent: October 28, 2014Assignee: Inventia Healthcare Private LimitedInventors: Sunil Beharilal Jaiswal, Ankur Janak Shah
-
Publication number: 20140314750Abstract: Described herein are methods of predicting the risk of developing ovarian cancer recurrence of a subject comprising the steps of detecting the expression levels of at least four of the six genes selected from the group consisting of AKT2, KRAS, RAC1, CALM3, RPS6KA2 and YWHAB or the gene products thereof, wherein the presence of increased expression levels of the genes or the gene products is predictive of the increased risk of developing ovarian cancer recurrence in the subject. Kits for practicing the methods are also disclosed.Type: ApplicationFiled: April 11, 2014Publication date: October 23, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Christina Kendziorski Newton, Kevin Hasegawa Eng
-
Publication number: 20140315844Abstract: Exemplary embodiments of the invention provide methods and compositions relating to a multi-gene signature, and subsets thereof, for predicting whether an individual with breast cancer will respond to chemotherapy based on expression of the genes in the multi-gene signature, as well as for prognosing risk of breast cancer metastasis.Type: ApplicationFiled: November 27, 2013Publication date: October 23, 2014Applicant: Celera CorporationInventors: Shirley KWOK, Alice WANG
-
Publication number: 20140301999Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Adalie Motta, Gary Schiltz, Georgeta Hategan, Timothy Hagen